Aytu BioPharma, Inc. (AYTU)
Automate Your Wheel Strategy on AYTU
With Tiblio's Option Bot, you can configure your own wheel strategy including AYTU - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AYTU
- Rev/Share 11.284
- Book/Share 5.6887
- PB 0.2619
- Debt/Equity 0.0532
- CurrentRatio 1.0255
- ROIC -0.0328
- MktCap 9193673.0
- FreeCF/Share -0.9355
- PFCF -1.602
- PE 5.5769
- Debt/Assets 0.015
- DivYield 0
- ROE 0.0532
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 1
- P/B Score 5
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock
Published: June 06, 2025 by: Accesswire
Sentiment: Neutral
Nantahala Capital Management, Stonepine Capital Management, Aytu Management, and New Institutional Shareholders Lead Financing. DENVER, CO / ACCESS Newswire / June 6, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced the pricing of an upsized public offering of 9,600,000 shares of common stock (or prefunded warrants in lieu thereof) at an effective public offering price of $1.50.
Read More
Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA(TM) (gepirone) Extended-Release Tablets in the United States
Published: June 06, 2025 by: Accesswire
Sentiment: Neutral
Aytu enters the over $22 billion United States prescription major depressive disorder ("MDD") market with the first-in-class oral selective serotonin 5HT1a receptor agonist for adults with MDD. EXXUA has demonstrated significant improvement in depression symptoms in clinical trials involving more than 5,000 patients and, notably, the incidence of sexual side effects experienced with EXXUA was comparable to placebo.
Read More
Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results
Published: February 12, 2025 by: Accesswire
Sentiment: Neutral
Net income of $0.8 million Adjusted EBITDA1 of $1.3 million Pediatric Portfolio net revenue up 86% sequentially First quarterly sequential prescription increase for both ADHD and Pediatric portfolios since Q2 fiscal 2023 $20.4 million cash balance at December 31, 2024 Company to host conference call and webcast today, February 12, 2025, at 4:30 p.m. Eastern time DENVER, CO / ACCESS Newswire / February 12, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced operational and financial results for the fiscal 2025 second quarter.
Read More
About Aytu BioPharma, Inc. (AYTU)
- IPO Date 2008-09-25
- Website https://aytubio.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Mr. Joshua R. Disbrow
- Employees 102